A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors

What is the purpose of this trial?

The purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of NHS-IL12 when given in combination with a fixed avelumab dose in subjects with metastatic or locally advanced solid tumors.



EMD Serono, Inc.

Dates: 08/11/2017 - 12/01/2018

Last Updated: 08/13/2017

Study HIC#: 2000020301

Get Involved

For more information about this study, contact:
Karen Forman
+1 203-671-0783
karen.forman@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Mario Sznol

Principal Investigator

Sub-Investigators